Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 976 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endothelial Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: acipimox, placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Graft-Versus-Host Disease
Interventions: Filgrastim; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fuchs Endothelial Dystrophy, Corneal Edema
Interventions: Descemet's stripping endothelial keratoplasty; Procedure
Lead sponsor: Cornea Research Foundation of America; Other
Eligibility: 21 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Kidney Failure, Chronic
Interventions: Repetitive arm exercise; Other
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Obesity
Interventions: Bradykinin; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HIV Infection, Inflammation, Cardiovascular Disease, HIV Infections
Interventions: raltegravir, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Obesity, Pre-hypertension, Hypertension
Interventions: L-citrulline supplementation, Whole Body Vibration Training; Dietary Supplement · Other
Lead sponsor: Florida State University; Other
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Fuchs' Corneal Endothelial Dystrophy (FCED)
Interventions: Part A Elamipretide 1.0% Ophthalmic Solution, Part B Elamipretide 3.0% Ophthalmic Solution, Part A Placebo, Part B Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Edgewood, Kentucky • Boston, Massachusetts

Conditions: Transplantation, Kidney, Cardiovascular Abnormalities, Cardiovascular Diseases
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Acute Myocardial Infarction
Interventions: Not listed
Lead sponsor: Scripps Translational Science Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 664 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Cognitive Impairment, Estrogen Deficiency, Menopause, Endothelial Dysfunction, Vascular Stiffness
Interventions: GnRHant + E2, GnRHant + Placebo; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Aurora, Colorado • Boulder, Colorado

Conditions: Posttraumatic Stress Disorder, Cardiovascular Diseases, Autonomic Dysfunction, Vascular Stiffness, Nightmare, Endothelial Dysfunction
Interventions: NightWare, Sham NightWare; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 22 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Cardiac Surgery
Interventions: Oxygen - normoxia, Oxygen - hyperoxia; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Stroke, Cerebrovascular Disorders
Interventions: Treadmill Exercise, Stretching/ROM; Behavioral
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 40 Years to 85 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ovarian Neoplasms, Ascites
Interventions: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Age-Related Macular Degeneration
Interventions: Loteprednol Etabonate Ophthalmic Gel [Lotemax], Refresh Lubricant Eye Drops [Artificial Tears]; Drug · Other
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Coronary Arteriosclerosis, Endothelial Dysfunction, Type 2 Diabetes Mellitus
Interventions: Aged Garlic Extract (AGE), Placebo; Dietary Supplement
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 30 Years to 75 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Torrance, California

Conditions: Kidney Injury, Proteinuria, Hypertension
Interventions: Isosorbide Mononitrate, Placebo oral tablet; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Preeclampsia Postpartum
Interventions: Losartan Potassium, Placebo; Drug
Lead sponsor: Anna Stanhewicz, PhD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Chest Pain
Interventions: Aspirin, Lisinopril, Simvastatin, Lovaza, Therapeutic Lifestyle Changes; Drug · Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 30 Years to 90 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Endothelial Dysfunction
Interventions: Carbon Monoxide; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 39 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Human Immunodeficiency Virus, Coronary Artery Disease
Interventions: Evolocumab; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hematopoietic Cell Transplantation
Interventions: Biorepository Trial; Other
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 26 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 3
States / cities: Rochester, Minnesota • Durham, North Carolina • Houston, Texas

Conditions: Diabetic Macular Edema
Interventions: CU06-1004, Single dose, CU06-1004, Multiple doses, Placebo; Drug
Lead sponsor: Curacle Co., Ltd.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Search by objective public record fields.

Free Fatty Acids and Vascular Function in Subjects With Diabetes

Tissue Repair in Stem Cell Transplant Recipients

Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty

Effect of Exercise on Endothelial Function and Vascular Compliance in Chronic Kidney Disease

Characterization of Brachial Arterial t-PA Release, Endothelial Function, Obesity and Inflammation

Effect of Raltegravir on Endothelial Function in HIV-Infected Patients

Whole Body Vibration Combined With L-citrulline Supplementation on Cardiovascular Function and Body Composition

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)

CEC/EPC and Cardiovascular Risk in Renal Transplant Recipients

Molecular and Morphologic Characterization of Circulating Endothelial Cells

Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function

NightWare and Cardiovascular Health in Adults With PTSD

Risk of Oxygen During Cardiac Surgery Trial

Effects of Exercise on Endothelial Function in Stroke Patients

Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain

Effect of Aged Garlic Extract (AGE) on Improving Coronary Atherosclerosis in People With Type 2 Diabetes Mellitus

Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury

Losartan for Improved Vascular Endothelial Function After Preeclampsia

Women With Chest Pain and Normal Coronary Arteries Study

Effects of Carbon Monoxide Breathing on Blood Vessel Function

Effect of Evolocumab on Coronary Endothelial Function

A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).

First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers